5,957,053 Shares in Boston Scientific Corporation $BSX Bought by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 5,957,053 shares of the medical equipment provider’s stock, valued at approximately $254,247,000. Deutsche Bank AG owned 0.41% of Boston Scientific at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of BSX. Kelleher Financial Advisors acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $25,000. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC bought a new stake in Boston Scientific in the fourth quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific during the first quarter valued at about $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 194,522 shares of company stock worth $9,385,210 in the last 90 days. Insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

BSX opened at $50.51 on Wednesday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market capitalization of $73.20 billion, a price-to-earnings ratio of 20.45, a P/E/G ratio of 1.13 and a beta of 0.56. The firm’s fifty day moving average price is $46.15 and its two-hundred day moving average price is $58.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

Several analysts have recently commented on BSX shares. Citigroup reduced their target price on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. BTIG Research dropped their price target on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Royal Bank Of Canada reduced their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, July 30th. Truist Financial decreased their price objective on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 target price on Boston Scientific in a report on Wednesday, July 29th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.